Rhumbline Advisers Autolus Therapeutics PLC Transaction History
Rhumbline Advisers
- $105 Billion
- Q2 2024
A detailed history of Rhumbline Advisers transactions in Autolus Therapeutics PLC stock. As of the latest transaction made, Rhumbline Advisers holds 5,802 shares of AUTL stock, worth $20,887. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5,802
Previous 2,314
150.73%
Holding current value
$20,887
Previous $14,000
42.86%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding AUTL
# of Institutions
114Shares Held
167MCall Options Held
34.2KPut Options Held
19.5K-
Syncona Portfolio LTD Guernsey, Channel Islands, X021.3MShares$76.8 Million86.45% of portfolio
-
Blackstone Inc New York, NY20.5MShares$73.7 Million0.31% of portfolio
-
Wellington Management Group LLP Boston, MA17.9MShares$64.4 Million0.01% of portfolio
-
Deep Track Capital, LP Greenwich, CT15.3MShares$55 Million1.74% of portfolio
-
Avoro Capital Advisors LLC New York, NY12.3MShares$44.4 Million0.59% of portfolio
About Autolus Therapeutics plc
- Ticker AUTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 90,909,800
- Market Cap $327M
- Description
- Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...